The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AAN, ANAB and GOSS
April 21, 2020 at 15:25 PM EDT
NEW YORK, NY / ACCESSWIRE / April 21, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Aarons, Inc. (NYSE:AAN)
The AAN lawsuit alleges Aarons, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) Aaron's had inadequate disclosure controls, procedures, and compliance measures; (ii) consequently, the operations of Aaron's Progressive Leasing ("Progressive") and Aaron's Business ("AB") segments were in violation of the Federal Trade Commission ("FTC") Act and/or relevant FTC regulations; (iii) consequently, Aaron's earnings from those segments were partially derived from unlawful business practices and were thus unsustainable; (iv) the full extent of Aaron's liability regarding the FTC's investigation into its Progressive and AB segments, Aaron's noncompliance with the FTC Act, and the likely negative consequences of all the foregoing on the Company's financial results; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in AAN: http://www.kleinstocklaw.com/pslra-1/aarons-inc-loss-submission-form?id=6117&from=1
AnaptysBio, Inc. (NASDAQ:ANAB)
AnaptysBio, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) AnaptysBio failed to disseminate important data from the Company's Phase 2a trial in atopic dermatitis, including the timing and extent of patients' use of topical corticosteroids as a rescue therapy during the study and whether any of the patients that utilized rescue therapy were classified as responders at a given time;and (ii) the Company's statements omitted key information from the Company's Phase 2a trial in peanut allergy, including patients' average cumulative peanut dose tolerated at day 14 after the administration of etokimab or placebo as well as whether the Company's decision to exclude 20% of the patients enrolled in the study from the interim analysis due to their mild symptoms was retrospective; and (ii) as a result of the foregoing, Defendants' positive statements about the efficacy and prospects of AnaptysBio's lead drug asset in the treatment of atopic dermatitis and peanut allergy were materially false and/or misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in ANAB: http://www.kleinstocklaw.com/pslra-1/anaptysbio-inc-loss-submission-form?id=6117&from=1
Gossamer Bio, Inc. (NASDAQ:GOSS)
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose: (1) the reasons for Gossamer's GB001 trial failures; (2) the purported clinical validation of Novartis' oral DP2 antagonist; and (3) that, as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in GOSS: http://www.kleinstocklaw.com/pslra-1/gossamer-bio-inc-loss-submission-form?id=6117&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: The Klein Law Firm
View source version on accesswire.com: